Compare AIMD & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIMD | BMRA |
|---|---|---|
| Founded | 1984 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 8.5M |
| IPO Year | 2008 | 1995 |
| Metric | AIMD | BMRA |
|---|---|---|
| Price | $0.62 | $1.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 28.4K | 10.1K |
| Earning Date | 11-12-2026 | 10-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | $124,157.00 | ★ $4,453,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 498.95 | N/A |
| 52 Week Low | $0.68 | $1.45 |
| 52 Week High | $3.88 | $2.94 |
| Indicator | AIMD | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 15.87 | 37.65 |
| Support Level | N/A | $1.50 |
| Resistance Level | $1.63 | $2.23 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 15.04 | 36.84 |
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.